99mTc-MIBI SPECT in primary hyperparathyroidism: Influence of concomitant vitamin D deficiency for visualization of parathyroid adenomas

NuklearMedizin

Volumn 47, Issue 1, 2008, Pages 1-7

  Schmidt, Matthias ^a,c   Thoma, N ^a   Dietlein, M ^a   Moka, D ^a   Eschner, W ^a   Faust, M ^a   Schroder W ^a   Von Hulst Schlabrendorff M ^b   Ehses, W ^b   Schicha, H ^a  

^a UNIVERSITY OF COLOGNE   (Germany)

^b Endocrinology Clinic   (Germany)

^c UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

Author keywords

25 OH vitamin D deficiency; 99mTc MIBI scintigraphy; Parathyroid hormone; Planar and SPECT imaging; Primary hyperparathyroidism; Single tracer dual phase protocol

Indexed keywords

METHOXY ISOBUTYL ISONITRILE TECHNETIUM TC 99M; PERTECHNETIC ACID TC 99M; DIAGNOSTIC AGENT; PARATHYROID HORMONE; RADIOPHARMACEUTICAL AGENT;

ADULT; AGED; ARTICLE; DISEASE ASSOCIATION; FEMALE; HISTOPATHOLOGY; HORMONE BLOOD LEVEL; HUMAN; HUMAN TISSUE; HYPERPARATHYROIDISM; MAJOR CLINICAL STUDY; MALE; PARATHYROID ADENOMA; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; SYMPTOM; THYROID SCINTISCANNING; ULTRASOUND; VITAMIN D DEFICIENCY; ADENOMA; BLOOD; ECHOGRAPHY; ORGAN SIZE; PARATHYROID TUMOR; PATHOLOGY; RETROSPECTIVE STUDY; SCINTISCANNING;

ADENOMA; HUMANS; HYPERPARATHYROIDISM; ORGAN SIZE; PARATHYROID HORMONE; PARATHYROID NEOPLASMS; RADIOPHARMACEUTICALS; RETROSPECTIVE STUDIES; TECHNETIUM TC 99M SESTAMIBI; VITAMIN D DEFICIENCY;

EID: 39449138987     PISSN: 00295566     EISSN: None     Source Type: Journal    
DOI: 10.3413/nukmed-0057     Document Type: Article

References (39)

1. Albright F. A page out of the history of hyperparathyroidism. J Clin Endocrinol 1948; 8: 637-657.
2. Bandeira F, Caldas G, Freese E et al. Relationship between serum vitamin D status and clinical manifestations of primary hyperparathyroidism. Endocr Practice 2002; 8: 266-270.
3. Bauer W, Federman DD. Hyperparathyroidism epitomized: the case of Captain Charles E. Martell. Metabolism 1962; 11: 21-29.
4. Bekis R, Aydin A, Tasci C et al. The role of gamma probe activity counts in minimally invasive parathyroidectomy. Preliminary results. Nuklearmedizin 2004; 43: 190-194.
5. Bénard F, Lefebvre B, Beuvon F et al. Rapid washout of Technetium-99m-MIBI from a large parathyroid adenoma J Nucl Med 1995; 36: 241-243.
6. Billotey C, Sarfati E, Aurengo A et al. Advantages of SPECT in Technetium-99m-sestamibi parathyroid scintigraphy. J Nucl Med 1996; 37: 1773-1778.
7. Borley NR, Collins REC, O'Doherty M et al. Technetium-99m sestamibi parathyroid localization is accurate enough for scan-directed unilateral neck exploration. Br J Surg 1996; 83: 989-991.
8. Brain HP, Sharma AK, Nussey SS. Hypothesis: the case for quaternary hyperparathyroidism. Med Hypotheses 2004; 62: 701-703.
9. Bussey AD, Bruder JM. Urinary calcium excretion in primary hyperparathyroidism: relationship to 25-hydroxyvitamin D status. Endocr Pract 2005; 11: 37-42.
10. 99mTc sestamibi - a new agent for parathyroid imaging. Nucl Med Comm 1989; 10: 791-794.
11. Greenspan BS, Brown ML, Dillehay GL et al. Procedure guideline for parathyroid scintigraphy. J Nucl Med 1998; 39: 1111-1114.
12. Grey A, Lucas J, Horne A et al. Vitamin D repletion in patients with primary hyperparathyroidism and coexistent vitamin D insufficiency. J Clin Endocrinol Metab 2005; 90: 2122-2126.
13. Hannon RR, Shorr E, McClellan WS et al. A case of osteitis fibrosa cystica (osteomalacia) with evidence of hyperactivity of the parathyroid bodies. Metabolic study I. J Clin Invest 1930; 8: 215-227.
14. Harinarayan CV, Gupta N, Kochupillai N. Vitamin D status in primary hyperparathyroidism in India. Clin Endocrinol (Oxf) 1995; 43: 351-358.
15. Klingler PJ, Strolz S, Profanter C et al. Management of hyperparathyroidism in an endemic goiter area. Worl J Surg 1998; 22: 301-308.
16. Krubsack AJ, Wilson SD, Lawson TL et al. Prospective comparison of radionuclide, computed tomographic, sonography, and magnetic resonance localization of parathyroid tumors. Surgery 1989; 106: 639-644.
17. Leslie WD, Riese KT, Dupont JO et al. Parathyroid adenomas without sestamibi retention. Clin Nucl Med 1995; 20: 699-702.
18. Lumb GA, Stanbury SW. Parathyroid function in human vitamin D deficiency and vitamin D deficiency in primary hyperparathyroidism. Am J Med 1974; 56: 833-839.
19. Mariani G, Gulec SA, Rubello D et al. Preoperative localization and radioguided parathyroid surgery. J Nucl Med 2003; 44: 1443-1458.
20. Moka D, Eschner W, Voth E et al. Iterative reconstruction: an improvement of technetium-99m MIBI SPET for the detection of parathyroid adenomas? Eur J Nucl Med 2000; 27: 485-489.
21. 99mTc-MIBI-SPECT: a highly sensitive diagnostic tool for localization of parathyroid adenomas. Surgery 2000; 128: 29-35.
22. 99mTc-MIBI-SPECT parathyroid gland scintigraphy for the preoperative localization of small parathyroid gland adenomas. Nuklearmedizin 1997; 36: 240-244.
23. Moosgaard B, Vestergaard P, Heickendorff L et al. Vitamin D status, seasonal variations, parathyroid adenoma weight and bone mineral density in primary hyperparathyroidism. Clin Endocrinol 2005; 63: 506-513.
24. Moosgaard B, Vestergaard P, Heickendorff L et al. Plasma 25-hydroxyvitamin D and not 1,25-dihydroxyvitamin D is associated with parathyroid adenoma secretion in primary hyperparathyroidism: a cross-sectional study. Eur J Endocrinol 2006; 155: 237-244.
25. O'Doherty MJ, Kettle AG, Wells P et al. Parathyroid imaging with technetium-99m-sestamibi: preoperative localization and tissue uptake studies. J Nucl Med 1992; 33: 313-318.
26. Palestro CJ, Tomas MB, Tronco GG. Radionuclide imaging of the parathyroid glands. Semin Nucl Med 2005; 35: 266-276.
27. Petti GJ, Chonkich GD, Morgan JW. Unilateral parathyroidectomy: the value of the localizing scan. J Otolaryngol 1993; 22: 307-310.
28. Rao DS, Agarwal G, Talpos GB et al. Role of vitamin D and calcium nutrition in disease expression and parathyroid tumor growth in primary hyperparathyroidism: a global perspective. J Bone Miner Res 2002; 17 (suppl 2): N75-N80.
29. Rao DS, Honasoge M, Divine GW et al. Effect of vitamin D nutrition on parathyroid adenoma weight: pathogenetic and clinical implications. J Clin Endocrinol Met 2000; 85: 1054-1058.
30. Ruf J, Lopez Hanninen E, Steinmüller T et al. Preoperative localization of parathyroid glands. Use of MRI, scintigraphy, and image fusion. Nuklearmedizin 2004; 43: 85-90.
31. Safi S, Hassikou H, Messary A et al. Severe primary hyperparathyroidism and vitamin D deficiency. Ann Endocrinol 2004; 65: 226-232.
32. Sandrock D. Leitlinie für die Nebenschilddrüsenszintigraphie. Nuklearmedizin 1999; 38: 223-225.
33. Sandström I. On a new gland in man and several mammals (glandulae parathyreoideae). Upsala Läkareförenings Förhandlingar 1879-80; 15: 441-471.
34. 99mTc-sestamibi scintigraphy. Comparison between subtraction-and dual-phase technique. Nuklearmedizin 2006; 45: 115-121.
35. Spence HM. The life and death of Captain Charles Martell and kidney stone disease. J Urol 1984; 132: 1204-1207.
36. Staudenherz A, Abela C, Niederle B et al. Comparison and histopathological correlation of three parathyroid imaging methods in a population with a high prevalence of concomitant thyroid diseases. Eur J Nucl Med 1997; 24: 143-149.
37. Taillefer R, Boucher Y, Potvin C et al. Detection and localization of parathyroid adenomas in patients with hyperparathyroidism using a single radionuclide imaging procedure with technetium-99m-sestamibi (double-phase study). J Nucl Med 1992; 33: 1801-1807.
38. Tibblin S, Bondeson AG, Bondeson L et al. Surgical strategy in hyperparathyroidism due to solitary adenoma. Ann Surg 1994; 200: 776-784.
39. Woodhouse NJ, Doyle FH, Joplin GF. Vitamin D deficiency and primary hyperparathyroidism. Lancet 1971; 2: 283-286.